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Abstract Soluble Aß (Saß) is normally present at a low 
concentration in human plasma and cerebrospinal fluid. Although 
the factors involved in the regulation of Saß plasma levels are 
still unknown, we have explored its excretion in the urine as one 
of the possible homeostatic mechanisms. The presence of Saß in 
the urine was investigated via immunoprecipitation experiments 
with anti-Aß antibodies followed by detection and identification 
by immunoblot, MALDI mass spectrometry and sequence 
analysis. Soluble Aß (4.3 kDa) immunoreactivity was present 
in the urine of normal donors, Down's syndrome individuals as 
well as in patients with renal disorders exhibiting glomerular or 
mixed proteinuria. Edman degradation of the immunoprecipi-
tated material yielded the intact Aß N-terminus and mass spectra 
analysis indicated the existence of a major component at mlz 
4327, corresponding to the molecular mass of Aßl-40. Semi-
quantitative data obtained from the immunoprecipitation experi-
ments indicate that under normal conditions the daily excretion 
of intact Saß in the urine represents less than 1% of the 
circulating pool. 
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1. Introduction 
Amyloid beta (Aß) is the major constituent of the fibrils 
deposited into senile plaques and cerebral blood vessels of 
patients with Alzheimer's disease (AD), Down's syndrome 
(DS), Hereditary Cerebral Hemorrhage with Amyloidosis of 
Dutch origin and normal aging (reviewed in [1]). Although 
originally thought to be an aberrant degradation product of 
its precursor molecule ßPP, this peptide is now known to be a 
normal soluble component (Saß) present at very low concen-
tration in plasma and cerebrospinal fluid (CSF) [2-5]. The 
major form of Saß, Aßl-40, is homologous to the amyloid 
protein extracted from cerebrovascular lesions, although mi-
nor Saß species with heterogeneity and length similar to the 
Aß components deposited in senile plaques were also found in 
circulation [5,6]. Soluble Aß was also described as a normal 
component in brain parenchyma, from where it can be ex-
tracted in aqueous solutions. Interestingly, when soluble frac-
tions of AD and DS brain homogenates were compared with 
control brains, an increased amount of Saß was detected [7,8]. 
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This increase appears to precede the appearance of Aß depos-
its [9], suggesting that Saß species may indeed represent im-
mediate precursors of the deposited fibrils. However, the ori-
gin of the Aß deposited in the brain is still debatable; it may 
be locally synthesized, it may come from the circulation, or a 
combination of both sources. 
Soluble Aß circulates in plasma associated mainly with lip-
oprotein particles, specifically high-density lipoproteins 
(HDL), co-localizing with apolipoproteins J (apoJ), E 
(apoE) and A-I (apoA-I) [10]. All these apolipoproteins ex-
hibit high binding affinity for Aß peptides [11-13]. ApoJ, in 
particular, displays a very high-affinity interaction for non-
aggregated forms of the Aß peptides and has been shown to 
maintain and stabilize the peptide solubility in vitro [14]. Sev-
eral lines of evidence indicate that the blood-brain barrier 
(BBB) has the capability to regulate the brain uptake and 
clearance of Saß. For the brain uptake, at least two different 
receptor-transport mechanisms have been identified. One in-
volves the peptide when it is complexed to apoJ, a proposed 
carrier molecule for circulating Saß species. A 36-fold higher 
uptake than that of the extracellular space marker sucrose was 
found for the complex Aß-apoJ in the guinea pig vascular-
brain perfusión model. The receptor implicated in the BBB 
transport was identified as gp330 or megalin, the receptor for 
apoJ [15]. The other receptor transport mechanism pertains to 
the uptake of free Aß peptides and was studied in guinea-pigs 
[16,17], squirrel monkeys [18], mice [19] and rats [20]. The 
uptake of the free peptide, although one-fourth of that of 
the complex Aß-apoJ, is saturable and specific in the guin-
ea-pig brain perfusión model, compromising cell surface mol-
ecules that are not yet fully identified. One possible candidate 
is the receptor for advance glycation-end products (RAGE), a 
recently described receptor for Aß species [21]. 
The BBB also appears to regulate the clearance of brain 
Saß species. Infusion of 125I-labeled Aßl-40 into one lateral 
ventricle in the rat brain has shown that in as little as 3.5 min 
30% of the peptide was cleared from ventricular CSF. Ten 
minutes after infusion ~ 70% of the radioactivity disappeared 
from the brain and was recovered in the blood, liver, kidney 
and urine [22]. In order to clarify to which extent the urinary 
excretion of Saß might be an important mechanism for Saß 
clearance from the circulation, we have investigated its pres-
ence in urine from normal donors, in specimens from DS 
patients with normal levels of urinary proteins as well as in 
samples from individuals with different degree of glomerular 
or mixed glomerular-tubular proteinuria. Down's syndrome 
urines were studied since it is known that plasma Saß levels 
are elevated in these patients [23]. The methodology used 
herein, immunoprecipitation, immunoblot analysis, matrix-as-
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sisted laser desorption/ionization mass spectrometry (MAL-
DI-MS) and N-terminal sequence clearly identified the 
presence of Aßl -40 as the major Saß specie of human 
urine. 
2. Materials and methods 
2.1. Samples 
Twenty-four-hour urine specimens were collected from two normal 
donors (proteinuria < 5 mg/dl), three patients with glomerular pro-
teinuria (210-600 mg/dl), five patients with mixed glomerular-tubular 
proteinuria (7^120 mg/dl) and seven cases of DS (proteinuria < 5 mg/ 
dl). DS urines were kindly provided by Dr. K. Wisniewski (Institute 
for Basic Research at Staten Island) from well-characterized patients 
who had been subjected to chromosomal analysis. All samples were 
dialyzed against distilled water using 1000 Da cut-off membrane and 
lyophilized prior to use. 
2.2. Immunoprecipitation 
Fifty microliters of paramagnetic Dynabeads M-450 coated with 
goat anti-mouse IgG (Dynal) were allowed to interact for 3 h at 
room temperature with a mixture of 3 μΐ of monoclonal antibody 
6E10 (anti-Aß 1-17; Senetek) and 3 μΐ of monoclonal antibody 4G8 
(anti-Aß 17-24; Senetek). After incubation, unbound antibody was 
removed by washing the beads with 10 mM phosphate (Ph 7.4) con-
taining 150 mM NaCl (PBS) and 0.1% bovine serum albumin. For the 
immunoprecipitation experiments, 5 mg of urinary proteins were solu-
bilized in 1 ml of PBS, added to the tube containing the paramagnetic 
beads coated with anti-Aß antibodies and incubated overnight at 4°C. 
After the incubation, the beads were washed 3 times with PBS, «sus-
pended in Laemmli sample buffer and loaded onto the SDS-polyacryl-
amide gel. Alternatively, the beads were eluted with 10 μΐ of isopro-
pylic alcohol/water/formic acid (4:4:1) mixture and analyzed by 
MALDI-MS. 
2.3. Immunoblot analysis 
Immunoprecipitated samples were separated on Tris-Tricine 16% 
SDS-PAGE and electroblotted onto nitrocellulose membrane (Bio-
Rad) using 3-cyclohexylamino-l-propanesulphonic acid (pH 11) con-
taining 10%o methanol. Membranes were blocked for 1 h with 5% low-
fat milk in PBS containing 0.05% Tween-20 and incubated overnight 
with monoclonal 6E10 (1:500), followed by horseradish peroxidase-
labeled goat anti-mouse F(ab')2 (1:2000; Amersham). Immunoblots 
were visualized with an enhanced chemiluminescence (ECL) detection 
kit and exposed to Hyperfilm ECL (Amersham). The intensity of the 
bands was semi-quantitatively evaluated using a Umax Power-Look 
scanner and the NTH Image 1.60 software. 
2.4. Sequence analysis 
Twenty milligrams of urinary proteins from two cases of mixed 
glomerular-tubular proteinuria were separated on Tris-Tricine 16% 
SDS-PAGE and transferred to polyvinylidene difluoride membranes 
(Immobilon P, Millipore) using the same conditions described above. 
After transfer, the membrane was stained with Coomassie Blue and 
the 4.3 Kda protein bands were excised and sequenced on a 477A 
protein sequencer (Applied Biosystems). 
2.5. MALDI-MS 
Soluble Aß from the urine samples immunoprecipitated as de-
scribed above was eluted from the beads in 10 μΐ of water/isopropyl 
alcohol/formic acid (4:4:1) and subjected to MALDI-MS using the 
Table 1 
Estimation of mean Saß levels in urine samples 
Pathology n Proteinuria 
(mg/dl) 
Normal donors 2 < 5 
Down's syndrome 7 < 5 
Glomerular or mixed proteinuria 8 7-600 
Fig. 1. Western Blot analysis of immunoprecipitated Saß from urine 
samples. Fluorograms of the Saß immunoprecipitated (arrowhead) 
from 5 mg of urinary proteins from normal donors (lane 1), Down's 
Syndrome (lane 2) and non-demented individuals with glomerular 
(lane 3) or mixed proteinuria (lane 4). For comparison, lane 5 dis-
plays the immunoreactivity of 10 ng of synthetic peptide Aßl-40 im-
munoprecipitated under the same experimental conditions. 
dried droplet method with a-cyano-4-hydroxicynnamic acid solution 
as a matrix. Samples were processed at the Mass Spectrometry Fa-
cility at the Skirball Institute (NYU Medical Center). 
3. Results and discussion 
In order to identify the presence of Saß in the urine, we 
developed an immunoprecipitation method based on the use 
of paramagnetic beads coated with goat anti-mouse IgG that 
were coupled to anti-Aß monoclonal antibodies. Amongst the 
available antibodies immunoreactive with A ß we found that 
the mixture of 6E10 plus 4G8 allowed the highest recoveries 
and a high sensitivity. Under the conditions tested, immuno-
precipitation of 0.2 ng of synthetic Aßl -40 rendered a clearly 
visible 4 K d a band in the corresponding fluorograms. Parallel 
experiments using Protein A/G agarose reached the detection 
limit at 1.0 ng. 
For each immunoprecipitation experiment, 5 mg of urinary 
samples from either normal donors, patients with glomerular 
proteinuria, individuals with mixed glomerular-tubular pro-
teinuria, or DS patients were used. As indicated in Fig. 1, 
immunoblot analysis of the immunoprecipitated material after 
separation in SDS-PAGE revealed the presence of a specific 
immunoreactive band of about 4 K d a with identical electro-
phoretic mobility of that of synthetic Aßl -40 . Soluble Aß 
immunoreactivity was present in normal donors (proteinuria 
< 5 mg/dl) (lane 1), al though it was consistently more prom-
inent in DS samples exhibiting a similar degree of proteinuria 
( < 5 mg/dl) (lane 2). It was also detected in samples from 
patients with mixed glomerular-tubular proteinuria (7^120 
mg/dl) (lane 3) as well as predominant glomerular components 
(proteinuria 210-600 mg/dl) (lane 4). 
Densitometric analysis of the different bands allowed us to 
estimate the amount of Saß peptide present in each sample 
through the comparison with 10 ng of synthetic Aßl -40 pep-
tide immunoprecipitated under the same conditions (lane 5). 
Fo r the normal donors tested (proteinuria < 5 mg/dl), the 
excretion of Saß was calculated at 0.81 ±0 .26 ng/5 mg of 
Saß Excretion of Saß 
(ng/5 mg urinary proteins) (ng/24 h) 
0.81 ±0.26 13 ±4 
2.13±0.70 32± 11 
1.24 ±0.32 20-2000 
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Fig. 2. Mass spectrometry of immunoprecipitated Saß from urine 
samples. Aliquots of lyophilized urine samples (5 mg) were immuno-
precipitated using monoclonal antibodies 6E10 and 4G8 coupled to 
paramagnetic beads as described in Section 2. The immunoprecipi-
tated material was eluted using 10 μΐ of isopropyl alcohol/water/for-
mic acid (4:4:1) mixture, applied on the spectrometer's probe using 
the dried droplet method in alpha-cyano-4-hydroxycinnamic acid 
matrix, and analyzed by MALDI-MS. For calibration purposes, 
synthetic Aßl-40 was used as standard of mass. 
urinary proteins (13 ±4 ng/24 h). The Down's syndrome pa-
tients analyzed (all with proteinuria < 5 mg/dl) excreted a 
higher amount of Saß (2.13 ± 0.7 ng/5 mg of urinary proteins, 
equivalent to 32 ±11 ng/24 h), which might correlate with 
their higher plasma concentration [23] as a result of the 
gene dosage. Taking into consideration that the levels of 
Saß in plasma are in the range of 1 ng/ml [4,23] and that 
under normal conditions the volume of the urine excreted in 
a 24 h period is around 1-1.5 1, the daily excretion of Saß in 
the urine represent less than 1% of the total circulating pool. 
These values are obviously increased several fold in patients 
with either glomerular or mixed tubular-glomerular proteinu-
ria; in these cases, where the amount of urinary proteins can 
reach values of 600 mg/dl or more, the daily excretion of Saß 
could reach 2000 ng/24 h. It is possible that when there is loss 
of permselectivity, Saß complexes from the circulation could 
pass through the altered filtration barrier, accounting for the 
higher excretion of Saß (Table 1). 
The identity of Saß present in the urine samples was corro-
borated by N-terminal sequence analysis. The 4.3 Kda bands 
obtained upon immunoprecipitation of 20 mg of urinary pro-
teins from two cases of mixed glomerular-tubular proteinuria 
were transferred to a polyvinylidene difluoride membrane and 
subjected to automatic Edman degradation. The sequences 
DAEFRxDxGxEV and DAEFRhDsGYEV were obtained, 
corresponding to the intact N-terminus of Aß. No N-terminal 
heterogeneity was found in the samples analyzed. The mass 
spectrometry analysis of the immunoprecipitated samples 
showed a main signal at mlz 4327, corresponding to the mo-
lecular mass of native Aßl-40 (Fig. 2). In all the cases studied, 
the major specie identified in urine was the Aßl-40 in accord-
ance to that specie's predominance in plasma. 
The results presented here demonstrate that Saß is a normal 
component of human urine. Under normal conditions, where 
the renal filtration-resorption function is preserved, the 
amount of intact Saß excreted in the urine accounts for less 
than 1% of the total circulating pool, indicating that the ma-
jority of the circulating Saß is catabolized or excreted by a 
different mechanism. Due to the association of Saß with HDL 
particles, it is possible that Saß catabolic/excretory pathways 
may follow those of the lipoprotein particles. If this is the 
case, it would be expected that the liver would be the key 
organ involved in the catabolism of Saß and perhaps in the 
excretion of the peptide or its degradation products in the 
bile. Whether urinary Saß levels are altered in sporadic AD 
or in familial AD associated with either ßPP or presenilin 
mutations remains to be determined. However, in view of 
our data (Table 1), potential AD diagnostic methods based 
on the measurement of urine and/or plasma levels of Saß 
should simultaneously evaluate the coexistence of pathological 
conditions that can alter glomerular filtration and/or tubular 
resorption. 
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